JP2017512500A - 細胞工学のための方法および遺伝システム - Google Patents

細胞工学のための方法および遺伝システム Download PDF

Info

Publication number
JP2017512500A
JP2017512500A JP2017502922A JP2017502922A JP2017512500A JP 2017512500 A JP2017512500 A JP 2017512500A JP 2017502922 A JP2017502922 A JP 2017502922A JP 2017502922 A JP2017502922 A JP 2017502922A JP 2017512500 A JP2017512500 A JP 2017512500A
Authority
JP
Japan
Prior art keywords
lactobacillus
engineered
clostridium
bacteroides
host
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2017502922A
Other languages
English (en)
Japanese (ja)
Other versions
JP2017512500A5 (cg-RX-API-DMAC10.html
Inventor
パトリック ボイル，
パトリック ボイル，
レシュマ ピー． シェティー，
レシュマ ピー． シェティー，
Original Assignee
ギンゴー バイオワークス， インコーポレイテッド
ギンゴー バイオワークス， インコーポレイテッド
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=54196352&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=JP2017512500(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by ギンゴー バイオワークス， インコーポレイテッド, ギンゴー バイオワークス， インコーポレイテッド filed Critical ギンゴー バイオワークス， インコーポレイテッド
Publication of JP2017512500A publication Critical patent/JP2017512500A/ja
Publication of JP2017512500A5 publication Critical patent/JP2017512500A5/ja
Pending legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/66—Microorganisms or materials therefrom
    • A61K35/74—Bacteria
    • A61K35/741—Probiotics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/66—Microorganisms or materials therefrom
    • A61K35/74—Bacteria
    • A61K35/741—Probiotics
    • A61K35/744—Lactic acid bacteria, e.g. enterococci, pediococci, lactococci, streptococci or leuconostocs
    • A61K35/747—Lactobacilli, e.g. L. acidophilus or L. brevis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/02—Drugs for disorders of the urinary system of urine or of the urinary tract, e.g. urine acidifiers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/10—Processes for the isolation, preparation or purification of DNA or RNA
    • C12N15/102—Mutagenizing nucleic acids
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/111—General methods applicable to biologically active non-coding nucleic acids
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/14—Hydrolases (3)
    • C12N9/16—Hydrolases (3) acting on ester bonds (3.1)
    • C12N9/22—Ribonucleases [RNase]; Deoxyribonucleases [DNase]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K2035/11—Medicinal preparations comprising living procariotic cells
    • A61K2035/115—Probiotics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55588—Adjuvants of undefined constitution
    • A61K2039/55594—Adjuvants of undefined constitution from bacteria
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/10—Type of nucleic acid
    • C12N2310/20—Type of nucleic acid involving clustered regularly interspaced short palindromic repeats [CRISPR]
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2320/00—Applications; Uses
    • C12N2320/30—Special therapeutic applications

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical & Material Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Organic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biomedical Technology (AREA)
  • Molecular Biology (AREA)
  • General Health & Medical Sciences (AREA)
  • Wood Science & Technology (AREA)
  • Zoology (AREA)
  • Microbiology (AREA)
  • Biotechnology (AREA)
  • General Engineering & Computer Science (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Biochemistry (AREA)
  • Mycology (AREA)
  • Physics & Mathematics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Biophysics (AREA)
  • Plant Pathology (AREA)
  • Epidemiology (AREA)
  • Crystallography & Structural Chemistry (AREA)
  • Urology & Nephrology (AREA)
  • Dermatology (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Coloring Foods And Improving Nutritive Qualities (AREA)
JP2017502922A 2014-03-25 2015-03-25 細胞工学のための方法および遺伝システム Pending JP2017512500A (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201461970024P 2014-03-25 2014-03-25
US61/970,024 2014-03-25
PCT/US2015/022508 WO2015148680A1 (en) 2014-03-25 2015-03-25 Methods and genetic systems for cell engineering

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2020132873A Division JP2021000092A (ja) 2014-03-25 2020-08-05 細胞工学のための方法および遺伝システム

Publications (2)

Publication Number Publication Date
JP2017512500A true JP2017512500A (ja) 2017-05-25
JP2017512500A5 JP2017512500A5 (cg-RX-API-DMAC10.html) 2018-04-19

Family

ID=54196352

Family Applications (2)

Application Number Title Priority Date Filing Date
JP2017502922A Pending JP2017512500A (ja) 2014-03-25 2015-03-25 細胞工学のための方法および遺伝システム
JP2020132873A Pending JP2021000092A (ja) 2014-03-25 2020-08-05 細胞工学のための方法および遺伝システム

Family Applications After (1)

Application Number Title Priority Date Filing Date
JP2020132873A Pending JP2021000092A (ja) 2014-03-25 2020-08-05 細胞工学のための方法および遺伝システム

Country Status (7)

Country Link
US (1) US20170173086A1 (cg-RX-API-DMAC10.html)
EP (1) EP3122870B1 (cg-RX-API-DMAC10.html)
JP (2) JP2017512500A (cg-RX-API-DMAC10.html)
AU (1) AU2015236045B2 (cg-RX-API-DMAC10.html)
CA (1) CA2943775A1 (cg-RX-API-DMAC10.html)
DK (1) DK3122870T3 (cg-RX-API-DMAC10.html)
WO (1) WO2015148680A1 (cg-RX-API-DMAC10.html)

Cited By (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2022533080A (ja) * 2019-05-12 2022-07-21 フォリアム フード サイエンス リミテッド 抗菌剤および方法
JP2022549519A (ja) * 2019-09-30 2022-11-25 シグマ－アルドリッチ・カンパニー・リミテッド・ライアビリティ・カンパニー 標的化ヌクレアーゼを用いたマイクロバイオータ組成の調節
JP2023507163A (ja) * 2019-12-17 2023-02-21 シグマ－アルドリッチ・カンパニー・リミテッド・ライアビリティ・カンパニー バクテロイデスにおけるゲノム編集

Families Citing this family (70)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2013066438A2 (en) 2011-07-22 2013-05-10 President And Fellows Of Harvard College Evaluation and improvement of nuclease cleavage specificity
WO2014160059A1 (en) 2013-03-13 2014-10-02 Gen9, Inc. Compositions and methods for synthesis of high fidelity oligonucleotides
US9163284B2 (en) 2013-08-09 2015-10-20 President And Fellows Of Harvard College Methods for identifying a target site of a Cas9 nuclease
US9359599B2 (en) 2013-08-22 2016-06-07 President And Fellows Of Harvard College Engineered transcription activator-like effector (TALE) domains and uses thereof
US9526784B2 (en) 2013-09-06 2016-12-27 President And Fellows Of Harvard College Delivery system for functional nucleases
US9340799B2 (en) 2013-09-06 2016-05-17 President And Fellows Of Harvard College MRNA-sensing switchable gRNAs
US9322037B2 (en) 2013-09-06 2016-04-26 President And Fellows Of Harvard College Cas9-FokI fusion proteins and uses thereof
US10584358B2 (en) 2013-10-30 2020-03-10 North Carolina State University Compositions and methods related to a type-II CRISPR-Cas system in Lactobacillus buchneri
CN111218447B (zh) 2013-11-07 2024-10-11 爱迪塔斯医药有限公司 使用统治型gRNA的CRISPR相关方法和组合物
US20150166984A1 (en) 2013-12-12 2015-06-18 President And Fellows Of Harvard College Methods for correcting alpha-antitrypsin point mutations
US10787654B2 (en) 2014-01-24 2020-09-29 North Carolina State University Methods and compositions for sequence guiding Cas9 targeting
AU2015236045B2 (en) 2014-03-25 2021-09-23 Ginkgo Bioworks, Inc. Methods and genetic systems for cell engineering
EP3129490A4 (en) 2014-04-08 2017-10-04 North Carolina State University Methods and compositions for rna-directed repression of transcription using crispr-associated genes
AU2015298571B2 (en) 2014-07-30 2020-09-03 President And Fellows Of Harvard College Cas9 proteins including ligand-dependent inteins
US10450584B2 (en) 2014-08-28 2019-10-22 North Carolina State University Cas9 proteins and guiding features for DNA targeting and genome editing
WO2016177682A1 (en) 2015-05-06 2016-11-10 Snipr Technologies Limited Altering microbial populations & modifying microbiota
WO2016196361A1 (en) 2015-05-29 2016-12-08 North Carolina State University Methods for screening bacteria, archaea, algae, and yeast using crispr nucleic acids
AU2016280002B2 (en) 2015-06-15 2022-04-14 North Carolina State University Methods and compositions for efficient delivery of nucleic acids and RNA-based antimicrobials
US11286480B2 (en) 2015-09-28 2022-03-29 North Carolina State University Methods and compositions for sequence specific antimicrobials
WO2017070632A2 (en) 2015-10-23 2017-04-27 President And Fellows Of Harvard College Nucleobase editors and uses thereof
JP6821598B2 (ja) 2015-12-07 2021-01-27 ザイマージェン インコーポレイテッド Ｃｏｒｙｎｅｂａｃｔｅｒｉｕｍ ｇｌｕｔａｍｉｃｕｍ由来のプロモーター
US9988624B2 (en) 2015-12-07 2018-06-05 Zymergen Inc. Microbial strain improvement by a HTP genomic engineering platform
WO2017112620A1 (en) 2015-12-22 2017-06-29 North Carolina State University Methods and compositions for delivery of crispr based antimicrobials
EP4159848A1 (en) * 2015-12-29 2023-04-05 Monsanto Technology LLC Novel crispr-associated transposases and uses thereof
CN115919906A (zh) 2016-03-04 2023-04-07 加利福尼亚大学董事会 微生物聚生体及其用途
US11766461B2 (en) 2016-04-20 2023-09-26 The Board of Trustees of the Stanford Junior Compositions and methods for nucleic acid expression and protein secretion in Bacteroides
GB201609811D0 (en) 2016-06-05 2016-07-20 Snipr Technologies Ltd Methods, cells, systems, arrays, RNA and kits
EP3478833A4 (en) 2016-06-30 2019-10-02 Zymergen, Inc. METHOD FOR PRODUCING A BACTERIAL HEMOGLOBIN LIBRARY AND ITS USE
US10544411B2 (en) 2016-06-30 2020-01-28 Zymergen Inc. Methods for generating a glucose permease library and uses thereof
WO2018027078A1 (en) 2016-08-03 2018-02-08 President And Fellows Of Harard College Adenosine nucleobase editors and uses thereof
AU2017308889B2 (en) 2016-08-09 2023-11-09 President And Fellows Of Harvard College Programmable Cas9-recombinase fusion proteins and uses thereof
WO2018039438A1 (en) 2016-08-24 2018-03-01 President And Fellows Of Harvard College Incorporation of unnatural amino acids into proteins using base editing
KR20240007715A (ko) 2016-10-14 2024-01-16 프레지던트 앤드 펠로우즈 오브 하바드 칼리지 핵염기 에디터의 aav 전달
WO2018071841A1 (en) * 2016-10-14 2018-04-19 The Forsyth Institute Compositions and methods for evading bacterial defense mechanisms
US11566238B2 (en) 2016-12-15 2023-01-31 The Board Of Trustees Of The Leland Stanford Junior University Compositions and methods for modulating growth of a genetically modified gut bacterial cell
WO2018119359A1 (en) 2016-12-23 2018-06-28 President And Fellows Of Harvard College Editing of ccr5 receptor gene to protect against hiv infection
US11224624B2 (en) * 2017-02-14 2022-01-18 California Institute Of Technology Modulation of microbial synthesis of 4-etylphenol and 4-ethylphenyl sulfate in behavior and disease
WO2018165504A1 (en) 2017-03-09 2018-09-13 President And Fellows Of Harvard College Suppression of pain by gene editing
KR20190123328A (ko) 2017-03-09 2019-10-31 프레지던트 앤드 펠로우즈 오브 하바드 칼리지 암 백신
CN110914310A (zh) 2017-03-10 2020-03-24 哈佛大学的校长及成员们 胞嘧啶至鸟嘌呤碱基编辑器
IL306092A (en) 2017-03-23 2023-11-01 Harvard College Nucleic base editors that include nucleic acid programmable DNA binding proteins
US11560566B2 (en) 2017-05-12 2023-01-24 President And Fellows Of Harvard College Aptazyme-embedded guide RNAs for use with CRISPR-Cas9 in genome editing and transcriptional activation
EP3658573A1 (en) 2017-07-28 2020-06-03 President and Fellows of Harvard College Methods and compositions for evolving base editors using phage-assisted continuous evolution (pace)
EP3676376B1 (en) 2017-08-30 2025-01-15 President and Fellows of Harvard College High efficiency base editors comprising gam
CA3082251A1 (en) 2017-10-16 2019-04-25 The Broad Institute, Inc. Uses of adenosine base editors
US12406749B2 (en) 2017-12-15 2025-09-02 The Broad Institute, Inc. Systems and methods for predicting repair outcomes in genetic engineering
US10760075B2 (en) 2018-04-30 2020-09-01 Snipr Biome Aps Treating and preventing microbial infections
AU2019253714A1 (en) 2018-04-10 2020-11-26 Siolta Therapeutics, Inc. Microbial consortia
WO2019226953A1 (en) 2018-05-23 2019-11-28 The Broad Institute, Inc. Base editors and uses thereof
EP3820495A4 (en) 2018-07-09 2022-07-20 The Broad Institute Inc. RNA-PROGRAMMABLE EPIGENETIC RNA MODIFIERS AND THEIR USES
WO2020072250A1 (en) 2018-10-01 2020-04-09 North Carolina State University Recombinant type i crispr-cas system and uses thereof for genome modification and alteration of expression
US12264330B2 (en) 2018-10-01 2025-04-01 North Carolina State University Recombinant type I CRISPR-Cas system and uses thereof for killing target cells
US12203123B2 (en) 2018-10-01 2025-01-21 North Carolina State University Recombinant type I CRISPR-Cas system and uses thereof for screening for variant cells
US10711267B2 (en) 2018-10-01 2020-07-14 North Carolina State University Recombinant type I CRISPR-Cas system
US11851663B2 (en) 2018-10-14 2023-12-26 Snipr Biome Aps Single-vector type I vectors
WO2020092453A1 (en) 2018-10-29 2020-05-07 The Broad Institute, Inc. Nucleobase editors comprising geocas9 and uses thereof
US20220056457A1 (en) * 2018-12-11 2022-02-24 The University Of Western Ontario Cis conjugative plasmid system
CN109652570A (zh) * 2019-01-16 2019-04-19 中国人民解放军总医院 微生物在鉴别和/或区分不同种族个体中的应用
US12351837B2 (en) 2019-01-23 2025-07-08 The Broad Institute, Inc. Supernegatively charged proteins and uses thereof
CA3128507A1 (en) 2019-02-06 2020-08-13 Fred Hutchinson Cancer Research Center Minicircle producing bacteria engineered to differentially methylate nucleic acid molecules therein
WO2020181264A1 (en) 2019-03-07 2020-09-10 The Trustees Of Columbia University In The City Of New York Rna-guided dna integration using tn7-like transposons
WO2020191241A1 (en) 2019-03-19 2020-09-24 The Broad Institute, Inc. Methods and compositions for editing nucleotide sequences
WO2020214842A1 (en) 2019-04-17 2020-10-22 The Broad Institute, Inc. Adenine base editors with reduced off-target effects
JP7624449B2 (ja) 2019-10-07 2025-01-30 シオルタ・セラピューティクス，インコーポレイテッド 治療用医薬組成物
US12435330B2 (en) 2019-10-10 2025-10-07 The Broad Institute, Inc. Methods and compositions for prime editing RNA
WO2021119594A1 (en) * 2019-12-13 2021-06-17 The Regents Of The University Of California Reducing antibiotic resistance in bacteria using pro-active genetics
CA3177481A1 (en) 2020-05-08 2021-11-11 David R. Liu Methods and compositions for simultaneous editing of both strands of a target double-stranded nucleotide sequence
CN112029699B (zh) * 2020-11-04 2021-06-08 中国农业科学院北京畜牧兽医研究所 一种基于内源CRISPR-Cas系统的丁酸梭菌基因编辑系统及其应用
US11851664B2 (en) 2020-12-24 2023-12-26 Oakbio, Inc. Methods for producing biochemicals using enzyme genes derived from a strain of Brevundimonas, and compositions made thereby
GB202209518D0 (en) 2022-06-29 2022-08-10 Snipr Biome Aps Treating & preventing E coli infections

Citations (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5627072A (en) * 1990-11-23 1997-05-06 Van Den Bergh Foods Co., Division Of Conopco Inc. Food-grade vector suitable for transforming a food-grade host cell use of said vector for transforming food-grade host cells and use of said transformed cells in biotransformation processes
US20030041352A1 (en) * 2000-03-08 2003-02-27 Wayne Parrott Arabitol or ribitol as positive selectable markers
JP2005519872A (ja) * 2001-11-12 2005-07-07 ファルマシア アンド アップジョン カンパニー リミティド ライアビリティー カンパニー サルモネラ・ワクチン
JP2010057406A (ja) * 2008-09-03 2010-03-18 National Agriculture & Food Research Organization 外来遺伝子を導入しない、非遺伝子組換えの遺伝子欠損株とその作製および選抜方法
JP2013501520A (ja) * 2009-08-11 2013-01-17 サンガモ バイオサイエンシーズ， インコーポレイテッド 標的改変によるホモ接合生物
JP2013520165A (ja) * 2010-02-18 2013-06-06 セレクティス 改善されたメガヌクレアーゼ組換え系

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR101311562B1 (ko) * 2003-08-14 2013-09-26 디에스엠 아이피 어셋츠 비.브이. 미생물을 이용한 ｌ-아스코르브산의 생산
FI116068B (fi) 2003-09-15 2005-09-15 Fit Biotech Oyj Plc Uusi selektiojärjestelmä, siinä käyttökelpoinen vektori, bakteerisolukantoja sekä menetelmä solujen valikoimiseksi
ES2473625T3 (es) * 2007-10-26 2014-07-07 Brenda E. Moore Composición probi�tica y métodos para inducir y mantener la pérdida de peso
DK2630156T3 (en) 2010-10-20 2018-12-17 Dupont Nutrition Biosci Aps CRISPR-CAS SEQUENCES OF LACTOCOCCUS
ES2728782T3 (es) * 2012-05-25 2019-10-28 Univ California Métodos y composiciones para la modificación de ADN objetivo dirigida por ARN y para la modulación de la transcripción dirigida por ARN
EP4074330A1 (en) * 2013-09-05 2022-10-19 Massachusetts Institute of Technology Tuning microbial populations with programmable nucleases
AU2015236045B2 (en) 2014-03-25 2021-09-23 Ginkgo Bioworks, Inc. Methods and genetic systems for cell engineering

Patent Citations (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5627072A (en) * 1990-11-23 1997-05-06 Van Den Bergh Foods Co., Division Of Conopco Inc. Food-grade vector suitable for transforming a food-grade host cell use of said vector for transforming food-grade host cells and use of said transformed cells in biotransformation processes
US20030041352A1 (en) * 2000-03-08 2003-02-27 Wayne Parrott Arabitol or ribitol as positive selectable markers
JP2005519872A (ja) * 2001-11-12 2005-07-07 ファルマシア アンド アップジョン カンパニー リミティド ライアビリティー カンパニー サルモネラ・ワクチン
JP2010057406A (ja) * 2008-09-03 2010-03-18 National Agriculture & Food Research Organization 外来遺伝子を導入しない、非遺伝子組換えの遺伝子欠損株とその作製および選抜方法
JP2013501520A (ja) * 2009-08-11 2013-01-17 サンガモ バイオサイエンシーズ， インコーポレイテッド 標的改変によるホモ接合生物
JP2013520165A (ja) * 2010-02-18 2013-06-06 セレクティス 改善されたメガヌクレアーゼ組換え系

Non-Patent Citations (5)

* Cited by examiner, † Cited by third party
Title
FEMS MICROBIOLOGY LETTERS (1998) VOL.167, PP.145-149, JPN6020013753, ISSN: 0004251063 *
FOOD MICROBIOLOGY (2006) VOL.23, PP.468-475, JPN6020013750, ISSN: 0004251062 *
PLOS ONE, vol. 8, no. 11, JPN6019019012, 2013, pages 80281, ISSN: 0004251059 *
SCIENCE (FEB-2013) VOL.339, NO.6121, P.819-823, JPN6019005014, ISSN: 0004251060 *
SCIENCE, vol. 343, JPN6019010246, 3 January 2014 (2014-01-03), pages 84 - 87, ISSN: 0004251061 *

Cited By (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2022533080A (ja) * 2019-05-12 2022-07-21 フォリアム フード サイエンス リミテッド 抗菌剤および方法
JP7588602B2 (ja) 2019-05-12 2024-11-22 フォリアム フード サイエンス リミテッド 抗菌剤および方法
JP2022549519A (ja) * 2019-09-30 2022-11-25 シグマ－アルドリッチ・カンパニー・リミテッド・ライアビリティ・カンパニー 標的化ヌクレアーゼを用いたマイクロバイオータ組成の調節
JP2024116193A (ja) * 2019-09-30 2024-08-27 シグマ－アルドリッチ・カンパニー・リミテッド・ライアビリティ・カンパニー 標的化ヌクレアーゼを用いたマイクロバイオータ組成の調節
JP2023507163A (ja) * 2019-12-17 2023-02-21 シグマ－アルドリッチ・カンパニー・リミテッド・ライアビリティ・カンパニー バクテロイデスにおけるゲノム編集

Also Published As

Publication number Publication date
DK3122870T3 (da) 2022-09-12
EP3122870A4 (en) 2017-08-30
EP3122870A1 (en) 2017-02-01
JP2021000092A (ja) 2021-01-07
US20170173086A1 (en) 2017-06-22
AU2015236045A1 (en) 2016-10-13
WO2015148680A1 (en) 2015-10-01
EP3122870B1 (en) 2022-06-29
AU2015236045B2 (en) 2021-09-23
CA2943775A1 (en) 2015-10-01

Similar Documents

Publication Publication Date Title
JP2021000092A (ja) 細胞工学のための方法および遺伝システム
Brödel et al. In situ targeted base editing of bacteria in the mouse gut
Dong et al. Exploiting a conjugative CRISPR/Cas9 system to eliminate plasmid harbouring the mcr-1 gene from Escherichia coli
Brigulla et al. Molecular aspects of gene transfer and foreign DNA acquisition in prokaryotes with regard to safety issues
Bron et al. Genetic characterization of the bile salt response in Lactobacillus plantarum and analysis of responsive promoters in vitro and in situ in the gastrointestinal tract
Walter et al. Identification of Lactobacillus reuteri genes specifically induced in the mouse gastrointestinal tract
US11591604B2 (en) Gene expression in Bacteroides
Sletvold et al. Complete sequence of Enterococcus faecium pVEF3 and the detection of an ω-ε-ζ toxin–antitoxin module and an ABC transporter
US20220403367A1 (en) Microbiome engineering through engineered mobile genetic elements
Sheng et al. Engineering conjugative CRISPR-Cas9 systems for the targeted control of enteric pathogens and antibiotic resistance
KR20220019697A (ko) 항박테리아제 및 방법
JP2024116193A (ja) 標的化ヌクレアーゼを用いたマイクロバイオータ組成の調節
Yu et al. Multiplex genome editing by natural transformation in Vibrio mimicus with potential application in attenuated vaccine development
EP3541942B1 (en) Conjugative vectors selectable by fructooligosaccharides
Neil et al. Assembly of large mobilizable genetic cargo by double recombinase operated insertion of DNA (DROID)
US8877502B2 (en) Plasmid curing
CA2420879C (en) Anti-microbial agents
Araya et al. Efficacy of plasmid-encoded CRISPR-Cas antimicrobial is affected by competitive factors found in wild Enterococcus faecalis isolates
CN116391040A (zh) 结合接合和Crispr/Cas系统的靶向抗菌质粒及其用途
Williams Genome instability in bacteria: causes and consequences
AU2001288542A1 (en) Anti-microbial agents
Platt et al. Development of a novel method of lytic phage delivery by use of a bacteriophage P22 site-specific recombination system
Xu et al. Eliminating the tigecycline resistance RND efflux pump gene cluster tmexCD-toprJ in bacteria using CRISPR/Cas9
US7758854B2 (en) Anti-microbial agents
JP7557777B2 (ja) アッカーマンシア種の遺伝子操作のためのシステムおよび方法

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20180307

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20180307

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20190527

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20190826

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20191028

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20191127

A02 Decision of refusal

Free format text: JAPANESE INTERMEDIATE CODE: A02

Effective date: 20200408